# Molecular Genetic Pathology * **Definition:** Molecular Genetic Pathology is a subspecialty of pathology that focuses on the diagnosis and characterization of diseases at the molecular level, utilizing techniques such as DNA sequencing, gene expression analysis, and other molecular assays to identify genetic mutations and alterations that contribute to disease processes. * **Taxonomy:** Specialties / Molecular Genetic Pathology ## News * Selected news on the topic of **Molecular Genetic Pathology**, for healthcare technology leaders * 2.6K news items are in the system for this topic * Posts have been filtered for tech-related keywords | Date | Title | Source | | --- | --- | --- | | 5/20/2025 | [**PCR Amplifier Market Signals: Trends and Investment Outlook - LinkedIn**](https://www.linkedin.com/pulse/pcr-amplifier-market-signals-trends-investment-outlook-rxqae/) | [[Linkedin]] | | 4/15/2025 | [**Illumina and Tempus look beyond cancer in new AI-driven genomics deal**](https://firstwordpharma.com/story/5950055) | [[FirstWord PHARMA]] | | 3/28/2025 | [**Cytogenetics Market Projected to Reach $5.5 Billion by 2031, Growing at a CAGR of 9.6rom 2024 --Exclusive Report by Meticulous Research®**](https://www.prnewswire.com/news-releases/cytogenetics-market-projected-to-reach-5-5-billion-by-2031--growing-at-a-cagr-of-9-6-from-2024-exclusive-report-by-meticulous-research-302414363.html) | [[PR Newswire]] | | 3/28/2025 | [**Cytogenetics Market Projected to Reach $5.5 Billion by 2031, Growing at a CAGR of 9.6 ...**](https://finance.yahoo.com/news/cytogenetics-market-projected-reach-5-135000505.html) | [[Yahoo Finance]] | | 12/31/2024 | [**DNA Sequencing Products Market 2024-32: Size, Share, Price Trends and Research Report**](http://prsync.com/imarc-group/dna-sequencing-products-market---size-share-price-trends-and-research-report-4537069/) | [[PRSync]] | | 12/30/2024 | [**Precision Medicine Software Research Analysis Report 2024-2030: Increasing Adoption of Genomic Data Analysis Software Spurs Growth, Integration of Multi-Omics Data Strengthens the Business Case - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241230952002/en/Precision-Medicine-Software-Research-Analysis-Report-2024-2030-Increasing-Adoption-of-Genomic-Data-Analysis-Software-Spurs-Growth-Integration-of-Multi-Omics-Data-Strengthens-the-Business-Case---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-Q-tiwWZwkcswR1UZtV7eGe24xL9TZOyQUMS3J72mJlQ7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LOzmn6JePCpHPCiYGaEx4DL1Rq8pNwkf3AarimpDzQGuQ==) | [[Business Wire]] | | 12/28/2024 | [**Artificial Intelligence - Healthcare IT News**](https://www.healthcareitnews.com/taxonomy/term/7341/m89gsv6dzcjz.jsp/page/2?type=video) | [[Healthcare IT News]] | | 11/29/2024 | [**Oligonucleotide Synthesis Market to grow by USD 3.37 Billion from 2024-2028, driven by ...**](https://www.prnewswire.com/news-releases/oligonucleotide-synthesis-market-to-grow-by-usd-3-37-billion-from-2024-2028--driven-by-rna-based-therapeutics-report-on-ais-impact-on-market-trends---technavio-302318087.html) | [[PR Newswire]] | | 11/18/2024 | [**Lilly unveils SGD$42M digital health innovation hub in Singapore - MobiHealthNews**](https://www.mobihealthnews.com/news/lilly-unveils-sgd42m-digital-health-innovation-hub-singapore) | [[MobiHealthNews]] | | 11/11/2024 | [**Population Health Management Market to Grow by USD 22.55 Billion from 2024-2028 ...**](https://www.prnewswire.com/news-releases/population-health-management-market-to-grow-by-usd-22-55-billion-from-2024-2028--driven-by-rising-adoption-of-healthcare-it-report-with-ai-impact-on-trends---technavio-302300769.html) | [[PR Newswire]] | | 11/11/2024 | [**The Evolution of the COVID-19 Molecular Diagnostics Market: Key Shifts from 2024 to 2031**](https://www.linkedin.com/pulse/evolution-covid-19-molecular-diagnostics-market-key-shifts-eewxe) | [[Linkedin]] | | 11/7/2024 | [**Next-Generation Sequencing (NGS) Services Market is expected to generate a revenue of ...**](https://www.prnewswire.com/news-releases/next-generation-sequencing-ngs-services-market-is-expected-to-generate-a-revenue-of-usd-18-35-billion-by-2031--globally-at-21-25-cagr-verified-market-research-302298672.html) | [[PR Newswire]] | | 10/28/2024 | [**DNA Synthesis Market to Grow by USD 6.5 Billion from 2024-2028, Driven by Rising Demand for DNA-Based Therapeutics, AI-Powered Report by Technavio**](https://www.prnewswire.com/news-releases/dna-synthesis-market-to-grow-by-usd-6-5-billion-from-2024-2028--driven-by-rising-demand-for-dna-based-therapeutics-ai-powered-report-by-technavio-302287660.html) | [[PR Newswire]] | | 10/24/2024 | [**Final Day of Global Health Exhibition Celebrates the Next Generation of Health Innovators**](https://www.prnewswire.com/ae/news-releases/final-day-of-global-health-exhibition-celebrates-the-next-generation-of-health-innovators-302285769.html) | [[PR Newswire]] | | 10/24/2024 | [**Final Day of Global Health Exhibition Celebrates the Next Generation of Health Innovators**](https://www.prnewswire.com/news-releases/final-day-of-global-health-exhibition-celebrates-the-next-generation-of-health-innovators-302285762.html) | [[PR Newswire]] | | 10/16/2024 | [**AI in Healthcare: Transforming Diagnosis and Treatment**](https://healthcareguys.com/2024/10/16/ai-in-healthcare-transforming-diagnosis-and-treatment/?utm_source=rss&utm_medium=rss&utm_campaign=ai-in-healthcare-transforming-diagnosis-and-treatment) | [[The Healthcare Guys]] | | 9/10/2024 | [**LH Stock Expected to Gain From the Ballad Health Acquisition Deal**](https://finance.yahoo.com/news/lh-stock-expected-gain-ballad-122400434.html) | [[Yahoo Finance]] | | 8/26/2024 | [**Aditxt's Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)**](http://www.businesswire.com/news/home/20240826381655/en/Aditxt%E2%80%99s-Precision-Health-Subsidiary-Pearsanta-Appoints-Christopher-Mitton-as-President-as-it-Seeks-to-Complete-Clinical-Validation-Studies-for-its-Mitomic%C2%AE-Endometriosis-Test-MET%E2%84%A2-and-Mitomic%C2%AE-Prostate-Test-MPT%E2%84%A2/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 7/3/2024 | [**BC Platforms Announces Appointment of New Chairman, Alex Dickinson - Yahoo Finance**](https://finance.yahoo.com/news/bc-platforms-announces-appointment-chairman-120000755.html) | [[Yahoo Finance]] | | 6/28/2024 | [**Genoks and Velsera Forge Strategic Partnership to Revolutionize Cancer Diagnostics in Turkey**](http://www.businesswire.com/news/home/20240628892797/en/Genoks-and-Velsera-Forge-Strategic-Partnership-to-Revolutionize-Cancer-Diagnostics-in-Turkey/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 6/26/2024 | [**Life Sciences IT Market Analysis 2024-2033: Size, Share, Trends, And Competitive Landscape**](https://menafn.com/1108378831/Life-Sciences-IT-Market-Analysis-2024-2033-Size-Share-Trends-And-Competitive-Landscape) | menafn.com | | 6/25/2024 | [**BioAI and Genomic Testing Cooperative Announce Strategic Collaboration to Provide AI-Powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications**](https://www.prnewswire.com/news-releases/bioai-and-genomic-testing-cooperative-announce-strategic-collaboration-to-provide-ai-powered-digital-pathology-solutions-for-clinical-research-and-diagnostic-applications-302181005.html) | [[PR Newswire]] | | 6/16/2024 | [**Companion Diagnostics Market Size to Reach $13.74 Billion by 2030: Latest Report by Vantage Market Research**](https://www.prweb.com/releases/companion-diagnostics-market-size-to-reach-13-74-billion-by-2030-latest-report-by-vantage-market-research-302173034.html) | [[PRWeb]] | | 6/13/2024 | [**Flinn Foundation-Sponsored Study Identifies Three Bioscience Growth Areas to Advance Innovation and Economic Growth in Greater Phoenix**](http://www.businesswire.com/news/home/20240613324046/en/Flinn-Foundation-Sponsored-Study-Identifies-Three-Bioscience-Growth-Areas-to-Advance-Innovation-and-Economic-Growth-in-Greater-Phoenix/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 6/4/2024 | [**Unlocking the Power of Patient Data: A Catalyst for Precision Medicine**](https://www.insideprecisionmedicine.com/topics/precision-medicine/unlocking-the-power-of-patient-data-a-catalyst-for-precision-medicine/) | [[Inside Precision Medicine]] | ## Specialty Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **BillionToOne**: A molecular diagnostics company specializing in prenatal screening and oncology diagnostics. - **Myriad Genetics**: A company collaborating with Flatiron Health to integrate hereditary cancer testing into electronic medical records. - **Thermo Fisher Scientific**: A major player in the molecular diagnostics market, providing tools and technologies for genetic analysis. - **Labcorp**: A global leader in laboratory services that has enhanced its genetic testing capabilities through acquisitions and partnerships. - **GeneDx**: Offers a data visualization tool for biopharmaceutical companies to enhance drug development processes using genetic data. - **CS Genetics**: Develops an innovative platform for single-cell genomics, enhancing accessibility and scalability in laboratory workflows. - **MGI Tech**: A company specializing in next-generation genomic sequencing technologies aimed at enhancing scientific research and personalized medicine. - **Pangea Biomed**: A biotechnology company specializing in advanced genetic profiling for cancer treatment predictions. - **Discovery Life Sciences**: A provider of biospecimen products and lab services for clinical research, specializing in molecular pathology. - **OncoHost**: A company specializing in precision medicine and cancer diagnostics, utilizing a proprietary proteomic platform. - **Genoks**: A genomics company enhancing cancer diagnostics and treatment. - **Agilent Technologies**: A leading company in the field of molecular diagnostics and oligonucleotide synthesis. - **datma**: A technology company providing a platform for genomic data sharing and collaboration among molecular labs. - **Caris Life Sciences**: A leader in precision medicine utilizing advanced molecular profiling and AI technologies to improve disease detection and treatment. - **Hadassah Cancer Research Institute**: Collaborates with Pangea Biomed to enhance cancer treatment predictions through genetic data integration. - **QIAGEN**: Known for its QIAcuityDx Digital PCR System, enhancing clinical diagnostics through precise quantitation of nucleic acids. - **ERS Genomics**: A company that holds a global portfolio of over 100 patents related to CRISPR/Cas9 technology, licensing it for commercial applications. - **BostonGene**: Utilizes AI-driven platforms for drug development and personalized cancer care, recognized for its contributions to oncology. - **Velsera**: A company providing clinical genomics solutions to improve diagnostic accuracy. ### Partnerships and Collaborations - **Takara Bio USA and Association for Molecular Pathology**: Showcasing the SmartChip ND Real-Time PCR System for infectious disease research. - **GeneDx and Biopharmaceutical Companies**: Collaboration to improve patient access to genetic testing and expedite treatment development for rare diseases. - **Centre for Population Genomics and Microsoft Research**: Establishing a consortium to improve genetic disease diagnosis through advanced analytics. - **Pangea Biomed and Hadassah**: Strategic collaboration to improve solid tumor treatment predictions through genetic profiling. - **datma and GOAL**: Collaboration to enhance genomic testing and promote data-driven insights for personalized medicine. - **Myriad Genetics and Flatiron Health**: Integration of MyRisk Hereditary Cancer Test into Flatiron's OncoEMR platform to streamline workflows for germline testing. - **BioAI and Genomic Testing Cooperative**: Collaboration to enhance biomarker discovery using multimodal AI. - **DNAnexus and Galatea Bio**: Collaboration to improve access to advanced genetic tools for underserved populations in Latin America. - **QIAGEN and Pharmaceutical Companies**: Partnerships for developing companion diagnostics to enhance personalized medicine. - **BioNexus Gene Lab Corp. and Shenzhen Rongguang Health Group**: Partnership to enhance cancer screening and precision medicine. - **Caris Precision Oncology Alliance**: A global network of cancer centers and research consortia collaborating to advance precision oncology and establish standards of care for molecular testing. - **Eli Lilly and Genetic Leap**: Collaboration to develop genetic medicine therapeutics using RNA-targeted AI technology. - **MGI Tech and Universidad de San Martín de Porres**: Partnership to implement advanced genomic sequencing for research in Peru. - **Harbinger Health and various conferences**: Showcasing innovations in blood-based early cancer detection and advancements in detecting circulating tumor DNA. - **Mainz Biomed and Thermo Fisher Scientific**: Collaborating to develop and commercialize a next-generation colorectal cancer screening product. - **Genoks and Velsera**: A partnership to enhance cancer diagnostics in Turkey by integrating advanced genomic analysis into Genoks' services. - **ERS Genomics and Université de Montréal**: A non-exclusive CRISPR/Cas9 license agreement allowing the university to access ERS's patent portfolio. ### Innovations, Trends, and Initiatives - **Molecular Genetic Pathology**: Advancements in molecular diagnostics are driving growth in the IVD reagents market, particularly in North America and Asia-Pacific. - **Precision medicine**: Growing trend towards personalized healthcare solutions based on genomic profiles. - **Digital Pathology**: Advancements in computational pathology utilizing AI for analyzing pathological image data. - **Cell-Free DNA Isolation Technologies**: Growing market driven by advancements in molecular diagnostics and personalized medicine. - **Bioinformatics Tools**: Essential for analyzing data generated by Next-Generation Sequencing (NGS) technologies, supporting diagnostics and medical treatment. - **Digital PCR Systems**: Advancements like QIAcuityDx enhance clinical testing capabilities for monitoring cancer progression. - **GeneDx Discover**: A novel data visualization tool providing access to deidentified genetic data for drug development. - **Clinical Genome Resource (ClinGen)**: Curating data on over 2,700 genes relevant to genetic diseases, aiming to standardize genomic information assessment for medical practice. - **Blood-based cancer detection**: Innovations in proprietary biomarkers for early cancer detection, improving screening accuracy. - **Liquid Biopsy**: Emerging as a non-invasive method for cancer detection, contributing to the growth of the molecular diagnostics market. - **AI-Driven Multiomics Platforms**: BostonGene's platform enhances drug development and clinical trials, optimizing patient-therapy matching. - **AI in Molecular Diagnostics**: The integration of AI technologies, such as machine learning, is driving advancements in diagnostic solutions and personalized medicine. - **DeepHRD Tool**: A new AI tool developed to enable rapid detection of genomic alterations from tumor biopsy slides, addressing delays in precision oncology. - **Next-Generation Sequencing (NGS)**: Rapid growth in NGS services driven by advancements in precision medicine and genomics. - **Integration of AI and Genomics**: Technological advancements are enhancing the capabilities of precision medicine software, allowing for more effective treatment plans. - **Thermal Cyclers Market Growth**: Projected growth in the thermal cyclers market due to increasing demand for molecular biology applications. - **CRISPR Technology**: Revolutionizing gene editing, increasing demand for synthetic oligonucleotides essential for diagnostics and therapeutics. - **AI in Pathology**: AI applications are being developed to analyze pathology images, providing insights for tumor analysis and treatment recommendations. - **DNA Synthesis Market**: Experiencing significant growth due to advancements in genomics research and the rising need for personalized medicine. ### Challenges and Concerns - **Disparities in molecular testing**: Identified as significant barriers to equitable care, prompting calls for enhanced education and collaboration. - **Integration of new technologies**: Challenges in integrating advanced genomic testing and molecular diagnostics into existing healthcare frameworks. - **Regulatory Hurdles**: Challenges in the adoption of new technologies in molecular diagnostics due to stringent regulations. - **Access to Technology**: Challenges in developing countries related to high costs and lack of skilled personnel in genomic technologies. - **Access to Precision Medicine**: There is a need for increased awareness among oncologists and patients regarding the accessibility of precision medicine tools. - **High Costs of Advanced Technologies**: Limit accessibility for smaller laboratories, hindering widespread adoption of advanced diagnostic tools. - **Data Management**: The ongoing challenges of virus variability and transmission chains highlight the importance of big data analysis in public health. - **Data Security**: Concerns regarding the security and standardization of genomic data sharing. - **Budget Constraints**: Developing countries face challenges in adopting advanced NGS technologies due to financial limitations. - **Technical Complexity**: Advanced thermal cyclers and other diagnostic tools may be difficult for smaller institutions to operate effectively. - **Market Competition**: The biotechnology reagents and kits market is highly competitive, necessitating continuous innovation and adaptation to market demands. - **Regulatory Approvals**: Favorable regulatory approvals are crucial for the adoption of new therapies, including antisense and RNAi therapies. - **Data Fragmentation**: Fragmented healthcare data hinders advancements in patient care and personalized treatment interventions. - **Complexity of Treatment Decisions**: Clinicians face challenges due to the complexity of individual patient circumstances and available treatment options. - **Regulatory Concerns**: Concerns over potential conflicts of interest in FDA collaborations with tech companies in health AI initiatives. - **High Costs of Drug Development**: The lengthy and expensive process of drug development, averaging $2.6 billion and 12 years, poses significant challenges. - **Integration of Digital Health Technologies**: The need for effective integration of digital technologies and data science into healthcare remains a challenge. - **Bias in AI Models**: Concerns about dataset biases and health inequities in low-income countries affecting AI implementation in healthcare. - **AI Training on Real Patient Data**: Nearly half of FDA-approved AI medical devices lack training on real patient data, raising concerns about their effectiveness. ## Related Topics [[Genetic Pathology]]; [[Molecular Diagnostics]]; [[Molecular Biology]]; [[Medical Genetics]]; [[Medical Biochemical Genetics]]; [[Clinical Genetics]]; [[Biochemical Genetics]]